Thomas Miller/Linkedin
Jun 16, 2025, 15:00
Thomas Miller: Unlocking Smarter BCL-2 Inhibitor Therapies After EHA 2025
Thomas Miller, Principal Investigator at Institut Paoli-Calmettes, shared a post on LinkedIn:
“Unlocking Smarter BCL-2 Inhibitor Therapies After EHA2025
Excellent final day at EHA2025. Institut Paoli-Calmettes was particularly engaged by the dedicated session on BCL-2 inhibitor therapies, highlighted by Sylvain Garciaz’s insightful presentation on inherent and acquired resistance mechanisms.
This critical discussion sparks a vital question: How can we develop smarter strategies to utilize BCL-2 inhibitors, circumvent multi-drug resistance, and unlock new combination opportunities, especially for the elderly patient population?
At Institut Paoli-Calmettes, we are committed to exploring these avenues, pushing the boundaries of research to enhance treatment efficacy and improve patient outcomes.
Let’s continue this crucial conversation and collaborate on innovative solutions!”
Find more posts featuring EHA 2025.
-
Aug 15, 2025, 23:36Irene M Lang's Editorial on Getting Risk Assessment Right in Acute Pulmonary Embolism
-
Aug 14, 2025, 23:47World Thrombosis Day: Know your Risk in DVT
-
Aug 14, 2025, 12:52JAMA Review: Immune Thrombotic Thrombocytopenic Purpura (iTTP)
-
Aug 14, 2025, 12:33Louise Bannon: The World Thrombosis Day Campaign is Calling on Industry Leaders
-
Aug 14, 2025, 10:58Thomas Reiser: Why October 13 Marks World Thrombosis Day?
-
Aug 15, 2025, 23:35SEC61B Mediated Platelet Hyperactivity in People with Diabetes
-
Aug 15, 2025, 23:32Fibrinogen Concentrate Safely Replaces Cryoprecipitate in Neonatal Cardiac Surgery
-
Aug 14, 2025, 23:47Health-related Quality of Life in Children with von Willebrand Disease
-
Aug 14, 2025, 17:54Omid Seidizadeh: From Genotype and Phenotype! Variability in Type 2 von Willebrand Disease
-
Aug 14, 2025, 17:36Samin Mohsenian: Thrombotic Paradox in Congenital Fibrinogen Deficiencies
-
Aug 14, 2025, 10:28Impressive 95% Clot Removal in a VTE Case: Symphony16F and Symphony24F Catheters
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Jul 26, 2025, 17:56HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Aug 15, 2025, 23:33Kacper Odziomek Excels in 2 Pharmacology Courses from Harvard Medical School
-
Aug 14, 2025, 02:08Jordan Harry's Conversation on Cancer and Clot Risk with Thrombosis Canada
-
Aug 13, 2025, 15:50Will Parsons Honors National Leaders in Hematology: Drs. Fasipe, Powers and Tubman
-
Aug 13, 2025, 10:25Joshua Muia on His HTRS Leadership Role Impact
-
Aug 11, 2025, 05:16Andreas Calatzis: Any Information on Soviet Thrombelastographs?
Aug 15, 2025, 23:35
Aug 15, 2025, 23:33
Aug 15, 2025, 14:23
Aug 14, 2025, 23:47
Aug 14, 2025, 23:47
Aug 14, 2025, 17:36